Katherine Gil

GLP-1 receptor agonists such as Ozempic have transformed the treatment of obesity, also reshaping the relationship with food by suppressing appetite and creating new nutritional challenges. In this context, the food industry has the opportunity to contribute to the well-being of people undergoing treatment with these drugs, helping to sustain their benefits, mitigate side effects, and meet new nutritional needs.

Mental and cognitive health is one of the major challenges of the 21st century, worsened by ageing and current lifestyles. This talk examines the role of nutrition in Brain Health and how to turn scientific evidence into measurable criteria for developing functional foods and ingredients. Eurecat will present tools and projects integrating in vitro models and human studies to assess efficacy and reduce risks in innovation.